In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Predicting 1-year mortality for patients undergoing transcatheter aortic valve implantation using charlson co-morbidity index

Session Moderated Poster 1: Interventional cardiology

Speaker Eva Cabrera Borrego

Congress : Acute Cardiovascular Care 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Interventional Cardiology - Other
  • Session type : Moderated Posters
  • FP Number : 35

Authors : E Cabrera-Borrego (Granada,ES), R Rivera-Lopez (Granada,ES), R Rubini-Costa (Granada,ES), V Alcaide-Martinez (Granada,ES), M Jimenez-Fernandez (Granada,ES), J Sanchez-Gila (Granada,ES), JA Romero-Hinojosa (Granada,ES), JA Ramirez-Hernandez (Granada,ES), J Pena-Mellado (Granada,ES), A Arriaga-Jimenez (Granada,ES), JM Sanchez-Moreno (Granada,ES), L Gonzalez-Camacho (Granada,ES), L Tercedor-Sanchez (Granada,ES), E Molina-Navarro (Granada,ES)

15 views

Authors:
E Cabrera-Borrego1 , R Rivera-Lopez1 , R Rubini-Costa1 , V Alcaide-Martinez1 , M Jimenez-Fernandez1 , J Sanchez-Gila1 , JA Romero-Hinojosa1 , JA Ramirez-Hernandez1 , J Pena-Mellado1 , A Arriaga-Jimenez1 , JM Sanchez-Moreno1 , L Gonzalez-Camacho1 , L Tercedor-Sanchez1 , E Molina-Navarro1 , 1University Hospital Virgen de las Nieves - Granada - Spain ,

Citation:

Introduction
The assessment of co-morbidity has become a basic need in the management of patients undergoing transcatheter aortic valve implantation (TAVI).

Purpose
To assess the performance of the Charlson co-morbidity index (CCI) predicting 1-year mortality in patients undergoing TAVI.

Methods
Prospective single-centre study of patients who underwent TAVI since 2010. To determine the co-morbidity, NYHA functional class, CCI, EuroSCORE I, EuroSCORE II and Society of Thoracic Surgeons (STS) score were recorded and multivariate regression model to predict 1-year mortality was performed. Subsequently, the best cut-off value for the CCI in predicting mortality was identified.

Results
241 patients were identified (mean age 80.3 ± 5.9, 51.2% males) with a mean STS score of 5.7 ± 4.8, EuroSCORE I and II of 16.6 ± 10.5 and 4.8 ± 3.9 respectively, and CCI of 5.7 ± 1.2. Most patients (84.2%) were in NYHA functional class III or IV and 1-year mortality was 16.4%. EuroSCORE I, II and STS score did not achieve significance (p=0.60, 0.94 and 0.28, respectively) and were not included in the multivariate logistic regression model to predict death. NYHA functional class I-II (reference value), III and IV were included in the model (OR: 1.4 and 4.8; p=0.03, respectively) as well as CCI (OR: 2.0; 95% CI 1.3-3-0; p=0.001). Patients with CCI =6 presented higher mortality (25.5 vs 5.4%, p=0.001) (OR: 5.9; 95% CI 2.1-16.1; p=0.001)

Conclusions
The CCI is a strong parameter predicting 1-year mortality and seems to be more valid predictor than surgery risk scores. Patients with CCI =6 have an important increased mortality risk. The 1-year mortality assessment with CCI is complemented by the NYHA functional class.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are